Search

Search Results

• P025 | PAIN RELIEF AFTER 30 MINUTES PREDICTS COMPLETE ACUTE TREATMENT SUCCESS AT 12 HOURS: A REAL-WORLD ANALYSIS OF INTRAVENOUS EPTINEZUMAB INFUSION IN HIGHLY REFRACTORY MIGRAINE PATIENTS

  L. Fofi¹, C. Altamura^1|2, M. Marcosano^1|2, L. d’Onofrio², A. Doretti³, F. Pistoia⁴, A. Granato⁵, S. Guerzoni⁶, M. Trimboli⁷, L. Grazzi⁸, D. Antonio Montisano⁸, G. Avino⁹, G. Sebastianelli¹⁰, C. Fasano¹¹, E. Maria Piella¹², P. Geppetti¹³, N. Brunelli¹, S. Lodico², L. Francesco Iannone¹⁴, F. Vernieri^1|2 | ¹Neurosonology and Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; ²Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; ³Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; ⁴Department of Biotechnological and Applied Clinical Sciences, Neurological Institute, University of L’Aquila, Italy; ⁵Headache Center, Neurology Clinic, University Hospital of Trieste, University of Trieste, Italy; ⁶Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinico di Modena, Italy; ⁷Azienda Ospedaliera-Universitaria “Renato Dulbecco”, Catanzaro, Italy; ⁸Headache Center, Department of Neurology, IRCCS Foundation “Carlo Besta” Neurological Institute, Milan, Italy; ⁹SOC Neurologia, Ospedale Santo Stefano, USL Toscana Centro, Prato, Italy; ¹⁰Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino ICOT, Sapienza University of Rome, Latina, Italy; ¹¹Headache and Cerebrovascular Diseases Center, Neurology Unit 2, Careggi University Hospital, Florence, Italy; ¹²Department of Neurosciences “Rita Levi Montalcini”, University of Turin, Italy; ¹³Department of Molecular Pathobiology and Pain Research Center, College of Dentistry, New York University, NY, United States; ¹⁴Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.15981

  • 0 abstract views
  • 0 PDF

• P015 | IMPROVING DISTRESS PERCEPTION IN CAREGIVERS OF MIGRAINE PATIENTS WITH DEPRESSIVE SYMPTOMS TREATED WITH FREMANEZUMAB. THE OBSERVATIONAL PROSPECTIVE REAL-LIFE MI-DEAR STUDY

  C. Altamura^1|2, L. Fofi¹, C. Aurilia³, E. Cresta⁴, A. Onofri⁵, A. Montisano⁶, M. Silvastro⁷, V. Favoni⁸, G. Viticchi⁹, M. Marcosano¹, G. Egeo³, M. Bartolini⁹, M. Peresson¹⁰, M. Cepparulo¹¹, A. Russo⁷, S. Cevoli⁸, R. Rao^4|12, L. Grazzi⁶, S. Sacco⁵, F. Vernieri^1|2 | ¹Neurosonology and Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; ²Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; ³Headache and Pain Unit, IRCCS San Raffaele Roma, Italy; ⁴Department of Frailty and Care, Neurology Unit, Headache Center, ASST Spedali Civili, Brescia, Italy; ⁵Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy; ⁶Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; ⁷Inter-departmental Program of Headache Medicine and Primary Pain Syndromes, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy; ⁸Programma cefalee e algie facciali, IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy; ⁹Neurological Clinic, Marche Polytechnic University, Ancona, Italy; ¹⁰Headache Unit, San Pietro Fatebenefratelli Hospital, Rome, Italy; ¹¹Teva Italia Srl, Milan, Italy; ¹²Department of Clinical and Experimental Sciences (DSCS), University of Brescia, Italy

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.15971

  • 0 abstract views
  • 0 PDF

• P041 | WHO TAKES CARE OF PATIENTS SUFFERING FROM MIGRAINE? THE CAREGIVER’S IDENTIKIT STUDY. A MI-DEAR SUB-ANALYSIS

  L. Fofi¹, C. Altamura^1|2, L. D'Onofrio¹, C. Aurilia³, E. Cresta⁴, A. Onofri⁵, A. Montisano⁶, M. Silvestro⁷, V. Favoni⁸, G. Viticchi⁹, M. Marcosano¹, G. Egeo³, M. Bartolini⁹, M. Peresson¹⁰, M. Cepparulo¹¹, A. Russo⁷, S. Cevoli⁸, R. Rao^4|12, L. Grazzi⁶, S. Sacco⁵, F. Vernieri^1|2 | ¹Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; ²Neurosonology and Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; ³Headache and Pain Unit, IRCCS San Raffaele Roma, Italy; ⁴Department of Frailty and Care, Neurology Unit, Headache Center, ASST Spedali Civili, Brescia, Italy; ⁵Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy; ⁶Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; ⁷Inter-departmental Program of Headache Medicine and Primary Pain Syndromes, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy; ⁸Programma cefalee e algie facciali, IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy; ⁹Neurological Clinic, Marche Polytechnic University, Ancona, Italy; ¹⁰Headache Unit, San Pietro Fatebenefratelli Hospital, Rome, Italy; ¹¹Teva Italia Srl, Milan, Italy; ¹²Department of Clinical and Experimental Sciences (DSCS), University of Brescia, Italy

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.15997

  • 0 abstract views
  • 0 PDF

• P112 | HOW MUCH DO YOU KNOW ABOUT MIGRAINE? UNMET CHALLENGES IN HEADACHE EDUCATION

  M. Marcosano^1|2, L. D’Onofrio^1|2, C. Altamura^1|2, L. Fofi^1|2, S. Lodico^1|2, F. Vernieri^1|2 | ¹Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; ²Neurology Unit, Università Campus Bio-Medico di Roma, Italy

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.16068

  • 0 abstract views
  • 0 PDF

• P016 | EFFECTIVENESS AND SAFETY OF MONTHLY VERSUS QUARTERLY FREMANEZUMAB FOR MIGRAINE PREVENTION: A 12 MONTHS ITALIAN, MULTICENTER, REAL-LIFE STUDY

  A. Antoniazzi¹, E. Ratto¹, I. Cetta¹, A. Visentini^1|2, L. Consuma^1|2, F. Genovese^1|2, L. Zanandrea^1|2, C. Lovati³, S. Cevoli⁴, V. Favoni⁴, F. Vernieri^5|6, C. Altamura^5|6, B. Colombo¹, M. Filippi^1|2, R. Messina^1|2 | ¹Headache Center, Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; ²Vita-Salute San Raffaele University, Milan, Italy; ³Headache Center, L. Sacco University Hospital, Milan, Italy; ⁴IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy; ⁵Unit of Headache and Neurosonology, Department of Medicine and Surgery, University Campus Bio-Medico di Roma, Italy; ⁶Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.15972

  • 0 abstract views
  • 0 PDF

• OC18 | LONG-TERM EFFECTIVENESS, SAFETY AND TOLERABILITY OF ATOGEPANT IN THE PREVENTION OF MIGRAINE: A MULTICENTRIC, PROSPECTIVE OBSERVATIONAL, REAL WORLD STUDY (THE 48-WEEK STAR STUDY)

  F. Vernieri^1|2, L. Francesco Iannone³, M. Marcosano^1|2, L. Fofi¹, F. Lo Castro⁴, G. Sebastianelli⁵, F. De Santis⁶, M. Corrado⁷, R. Ornello⁶, L. Grazzi⁸, D. Antonio Montisano⁸, F. De Cesaris⁹, A. Munafò⁹, G. Avino¹⁰, M. Trimboli¹¹, M. Albanese¹², A. Russo¹³, M. Silvestro¹³, G. Dalla Volta¹⁴, M. Romozzi¹⁵, P. Calabresi¹⁵, A. Boccalini⁴, P. Merlo¹⁶, M. Pia Prudenzano¹⁷, M. Rosaria Valente¹⁸, I. Rainero¹⁹, G. Giuliani²⁰, M. Altieri²⁰, A. Doretti²¹, G. Vaghi^7|22, F. Pistoia⁶, D. Ferrandi²³, S. Battistini²⁴, G. Coppola⁵, S. Guerzoni⁴, S. Sacco^6|25, C. Tassorelli^7|22, C. Altamura^1|2 | ¹Headache and Neurosonology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; ²Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; ³Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy; ⁴Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico Di Modena, Italy; ⁵Sapienza University of Rome, Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino, Latina, Italy; ⁶Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; ⁷Headache Science and Neurorehabilitation Centre, IRCCS Mondino Foundation, Pavia, Italy; ⁸Headache Center IRCCS Fondazione Istituto Neurologico "Carlo Besta", Italy; ⁹Headache center and clinical pharmacology, AOU Careggi, Firenze, Italy; ¹⁰Neurology Unit, Ospedale Santo Stefano, USL Toscana Centro, Prato, Italy; ¹¹Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro, Italy; ¹²Department of Systems Medicine, University of Rome Tor Vergata, Italy; ¹³Headache Center, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Italy; ¹⁴U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Italy; ¹⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; ¹⁶UO di Neurologia, Humanitas Gavazzeni, Bergamo, Italy; ¹⁷Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Italy; ¹⁸Clinica Neurologica ASUFC, Dipartimento di Medicina DMED Università di Udine, Italy; ¹⁹Headache Center, Department of Neuroscience, University of Torino, Italy; ²⁰Department of Human Neuroscience, Sapienza University of Rome, Italy; ²¹IRCCS Istituto Auxologico Italiano, Milano, Italy; ²²Department of Brain and Behavioural Sciences, University of Pavia, Italy; ²³SC Neurologia, Azienda Ospedaliero Universitaria Santi Antonio e Biagio, Alessandria, Italy; ²⁴Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy; ²⁵Neurology and Stroke Unit, ASL 1 Abruzzo, Avezzano-Sulmona-L’Aquila, Italy

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.15956

  • 0 abstract views
  • 0 PDF

• P032 | IMPROVEMENT IN DEPRESSIVE AND ANXIETY SYMPTOMS DURING EPTINEZUMAB TREATMENT: A POST-HOC ANALYSIS FROM THE TACHIS STUDY

  E.M. Piella¹, A.M. Chiarandon¹, V. Batti¹, D.A. Montisano², L. F. Iannone³, C. Fasano⁴, G. Sebastianelli⁵, G. Coppola⁵, D. Ferrandi⁶, C. Lanni⁷, M.P. Prudenzano⁸, M. De Tommaso⁹, P. Merlo¹⁰, A. Viganò¹⁰, F. De Cesaris¹¹, A. Chiarugi¹¹, A. Munafò¹¹, F. Pistoia¹², R. Ornello¹², S. Sacco¹², A. Doretti¹³, L. Grazzi², F. Lo Castro¹⁴, R. Allamprese¹⁴, R. De Icco^15|16, G. Vaghi^15|16, C. Tassorelli^15|16, G. Avino¹⁷, M. Romozzi¹⁸, C. Vollono¹⁸, P. Calabresi¹⁸, S. Battistini¹⁹, A. Rufa¹⁹, M. Albanese²⁰, M. Trimboli²¹, G. Carlucci⁴, M. Silvestro²², A. Russo²², M. Valente²³, L. Fofi²⁴, M. Marcosano²⁴, P. Geppetti²⁵, C. Altamura²⁴, F. Vernieri²⁴, E. Rubino¹, I. Rainero¹, S. Guerzoni¹⁴ | ¹Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Italy; ²Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy; ³Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy; ⁴NEUROFARBA Department, University of Florence - Neurologia, AOU Careggi, Italy; ⁵Sapienza University of Rome, Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino, Latina, Italy; ⁶AOU Alessandria, SC Neurologia, Italy; ⁷Psicologia AOU Alessandria, Italy; ⁸Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Consorziale di Bari, Italy; ⁹Neurophysiopathology Unit, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Italy; ¹⁰UO di Neurologia, Humanitas Gavazzeni, Bergamo, Italy; ¹¹Headache center and Clinical pharmacology unit, AOU Careggi, Florence, Italy; ¹²Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy; ¹³Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy; ¹⁴Digital and Predictive Medicine, Pharmacology, Clinical Metabolic Toxicology-Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico, Modena, Italy; ¹⁵Department of Brain and Behavioral Sciences, University of Pavia, Italy; ¹⁶Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy; ¹⁷SOC Neurologia, Ospedale di Prato, Italy; ¹⁸Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; ¹⁹Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy; ²⁰Unit of Neurology, Department of Systems Medicine, University of Rome Tor Vergata, Italy; ²¹Headache Center, Unit of Neurology, AOU Renato Dulbecco, Catanzaro, Italy; ²²Inter-departmental Program of Headache Medicine and Primary Pain Syndromes, Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy; ²³DMED, University of Udine and Clinical Neurology, Udine University Hospital, Italy; ²⁴Fondazione Policlinico Universitario Campus Bio-Medico, Roma e Università Campus Bio-Medico di Roma, Italy; ²⁵Department of Molecular Pathobiology and Pain Research Center, College of Dentistry, New York University, NY, USA

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.15988

  • 0 abstract views
  • 0 PDF

• P047 | ONABOTULINUMTOXIN-A EFFECTIVENESS EVALUATION IN CHRONIC MIGRAINE PATIENTS WITH SHORT OR LONG DISEASE HISTORY AND PSYCHIATRIC COMORBIDITIES: AN ITALIAN MULTICENTRIC STUDY (THE BACH STUDY)

  F. Vernieri^1|2, P. Pasqualetti³, M. Marcosano^1|2, N. Brunelli⁴, L. Fofi¹, D. Antonio Montisano⁵, L. Grazzi⁵, R. Ornello⁶, C. Rosignoli⁶, A. Doretti⁷, E. Colombo⁷, M. Albanese⁸, G. Viticchi⁹, S. Migliore⁶, S. Sacco⁶, C. Altamura^1|2 | ¹Headache and Neurosonology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; ²Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; ³Section of Health Statistics and Biometry, Department WHES (Wellbeing, Health & Environmental Sustainability), Sapienza University of Rome, Italy; ⁴Department of Neurology, Vall d’Hebron Research Institute, Barcelona, Spain; ⁵Headache Center, IRCCS Fondazione Istituto Neurologico "Carlo Besta", Milano, Italy; ⁶Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; ⁷Department of Systems Medicine, University of Rome Tor Vergata, Italy; ⁸IRCCS Istituto Auxologico Italiano, Milano, Italy; ⁹Neurological Clinic, Experimental and Clinical Medicine Department, Marche Polytechnic University, Ancona, Italy

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.16003

  • 0 abstract views
  • 0 PDF

• P105 | PATIENT DEPRESSIVE SYMPTOMS AND RECIPROCITY INFLUENCE DISTRESS IN THE CAREGIVER OF PATIENTS WITH MIGRAINE: INSIGHTS FROM THE MIDEAR OBSERVATIONAL COHORT STUDY

  C. Altamura^1|2, L. Fofi¹, C. Aurilia³, E. Cresta⁴, A. Onofri⁵, A. Montisano⁶, M. Silvastro⁷, V. Favoni⁸, G. Viticchi⁹, M. Marcosano¹, G. Egeo³, M. Bartolini⁹, M. Peresson¹⁰, M. Cepparulo¹¹, A. Russo⁷, S. Cevoli⁸, R. Rao^4|12, L. Grazzi⁶, S. Sacco⁵, F. Vernieri^1|2 | ¹Neurosonology and Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; ²Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; ³Headache and Pain Unit, IRCCS San Raffaele Roma, Italy; ⁴Department of Frailty and Care, Neurology Unit, Headache Center, ASST Spedali Civili, Brescia, Italy; ⁵Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy; ⁶Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; ⁷Inter-departmental Program of Headache Medicine and Primary Pain Syndromes, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy; ⁸Programma cefalee e algie facciali, IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy; ⁹Neurological Clinic, Marche Polytechnic University, Ancona, Italy; ¹⁰Headache Unit, San Pietro Fatebenefratelli Hospital, Rome, Italy; ¹¹Teva Italia Srl, Milan, Italy; ¹²Department of Clinical and Experimental Sciences (DSCS), University of Brescia, Italy

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.16061

  • 0 abstract views
  • 0 PDF